A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.
Experimental pill proved no better than Vertex’s blockbuster Trikafta alone
Adobe
By Jason MastAug. 10, 2026
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts…
Sionna Therapeutics’ shares fell more than 90% after reporting that its lead asset failed an early study and it is no longer…
Sionna Therapeutics topline clinical data for cystic fibrosis programs disappoints, opting to discontinue its SION-719 candidate.
The biotech said it will not advance SION-719 as an add-on therapy after the drug missed its key endpoint in a Phase 2a study
Vertex stock surged Monday after its competitor, Sionna, missed the mark for its highly anticipated cystic fibrosis treatment.
48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients.
